What is the 2025 treatment landscape of follicular lymphoma?
In this video, the panel discusses follicular lymphoma treatment options in 2025.
Lymphoma Roundtable
ASH 2025
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
SOHO 2026
Multiple Myeloma
News
Society Updates
Facing 2026 with a mix of inspiration and trepidation
"We have so much potential, so many lives dedicated to treatment and prevention of blood cancers, terabytes of data on immune function and
Trending now
ASH 2025
Myeloproliferative Neoplasms
Primary Myelofibrosis
Adam Mead, MD, on interim phase 1 PROMise trial results in myelofibrosis
In this video interview with SOHO Insider, Adam Mead, MD, professor of hematology at the University of Oxford and lead author on the
ASH 2025
Lymphoma
Aggressive B-Cell Lymphomas
Pearl van Heteren, MD, on the DALY 2-EU trial in R/R DLBCL
In this SOHO Insider interview, Pearl van Heteren, MD, medical director in clinical development (Europe) at Miltenyi Biomedicine, discusses the DALY-2 EU trial
Lymphoma Roundtable
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
How do you approach frontline patients in follicular lymphoma?
In this video, the group discusses approaching frontline follicular lymphoma patients, including determining patients who are high risk using symptoms and disease extent.
Lymphoma Roundtable
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
How do you approach a patient with POD24 in follicular lymphoma?
In this video, the group discusses managing POD24 follicular lymphoma patients, emphasizing clinical trials and preference for T-cell engaging therapies over chemotherapy and
Lymphoma Roundtable
Lymphoma
Aggressive B-Cell Lymphomas
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
What are the obstacles in using CELLMoDs in DLBCL?
In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at University of California, San Francisco, moderates a
ASH 2025
News
DOCK1 inhibition in TP53-mutant clonal hematopoiesis
Recorded at the 67th American Society of Hematology Annual Meeting and Exposition, Yang Feng, PhD, discusses her ASH abstract titled (No.631) “Targeting DOCK1
Lymphoma
Indolent B-Cell Lymphomas
News
EC approves tafasitamab combo in relapsed follicular lymphoma
The European Commission approved tafasitamab (Minjuvi) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (FL) grade
Lymphoma Roundtable
Lymphoma
Aggressive B-Cell Lymphomas
Indolent B-Cell Lymphomas
News
Video Interviews
What is the 2025 treatment landscape in DLBCL?
“We have gone from having R-CHOP and chemotherapy in the second link to to having an embarrassment of riches, basically a wealth of